Cargando…

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

Epirubicin, gemcitabine, and pirarubicin are widely used as first-line drugs for intravesical chemotherapy to prevent tumor recurrence after transurethral bladder tumor resection for non-muscle-invasive bladder cancer (NMIBC). However, which drug is better is less discussed. A total of 335 NMIBC pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jianglei, Li, Miao, Chen, Ze, OuYang, Jun, Ling, Zhixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651429/ https://www.ncbi.nlm.nih.gov/pubmed/34888022 http://dx.doi.org/10.1155/2021/2360717

Ejemplares similares

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer
por: Zhang, Bin, et al.
Publicado: (2023)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhiyu, Zhang, et al.
Publicado: (2021)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis
por: Zhuo, Chuanjun, et al.
Publicado: (2016)

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis
por: Liu, Kang, et al.
Publicado: (2020)

Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression
por: Delto, Joan C., et al.
Publicado: (2013)

Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis
por: Lu, Jun‐Lin, et al.
Publicado: (2020)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
por: Chen, Jian-Xin, et al.
Publicado: (2023)

Effect of continuous saline bladder irrigation with concomitant single instillation of chemotherapy after transurethral resection on intravesical recurrence in patients with non-muscle-invasive bladder cancer
por: Kuroda, Kenji, et al.
Publicado: (2020)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
por: Serretta, Vincenzo, et al.
Publicado: (2015)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
por: Douglass, Laura, et al.
Publicado: (2016)

Device-assisted intravesical therapy for non-muscle invasive bladder cancer
por: Hendricksen, Kees
Publicado: (2019)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
por: Cheng, Chunliang, et al.
Publicado: (2021)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor
por: Shao, Li-jun, et al.
Publicado: (2022)

Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer
por: Brummelhuis, Iris S. G., et al.
Publicado: (2021)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
por: Lammers, Rianne J. M., et al.
Publicado: (2015)

Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C
por: Lenis, Andrew T., et al.
Publicado: (2018)

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer
por: Woodcock, Victoria K., et al.
Publicado: (2023)

Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3(+) T cells in the primary transurethral resection of bladder tumor specimens
por: Murai, Ryosuke, et al.
Publicado: (2018)

Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer
por: Chen, Cheng‐Che, et al.
Publicado: (2023)

Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer
por: Matsuoka, Yuki, et al.
Publicado: (2021)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning
por: Ward, Kelly, et al.
Publicado: (2022)

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study
por: Zhou, Zhongbao, et al.
Publicado: (2021)

Is Intravesical Bacillus Calmette-Guérin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate
por: Han, Kyung-Sik, et al.
Publicado: (2015)

How to Perform Intravesical Chemotherapy after Second TURBT for Non-Muscle-Invasive Bladder Cancer: A Single-Center Experience
por: Li, Zhen, et al.
Publicado: (2022)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia
por: Wang, Chengbo, et al.
Publicado: (2023)

Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_prb4n77n6g52k82fl3lp33et77